POST Online Media Lite Edition



 

Allergan buys rights to Merck's migraine drugs

Staff writer |
Allergan plc and Merck, known as MSD outside the United States and Canada, entered into an agreement under which Allergan will acquire the exclusive worldwide rights to Merck's migraine drugs.

Article continues below






The rights are for Merck's investigational small molecule oral calcitonin gene-related peptide (CGRP) receptor antagonists, which are being developed for the treatment and prevention of migraine, subject to expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).

Under the terms of the agreement, Allergan will acquire these rights for an upfront payment of $250 million, $125 million of which is payable upon HSR clearance and $125 million of which is payable in April of 2016.

Merck will additionally be entitled to receive potential development and commercial milestone payments and tiered double-digit royalties based on commercialization of the programs.

Allergan will be fully responsible for development of the CGRP programs, as well as manufacturing and commercialization upon approval and launch of the products.

Allergan said its 2015 earnings-per-share forecast provided on May 11, 2015 is unchanged as a result of the acquisition. Allergan remains committed to de-levering to below 3.5x debt to Adjusted EBITDA by the end of the first quarter of 2016.


What to read next

Valeant boosts its offer for Allergan
Allergan to buy Zeltiq Aesthetics for $2.48 billion
U.S. House committee launches probe of Allergan patent hiding